RxDoctor Payments DataLook up a doctor →

Matthew Whitehurst, MD

Medical Oncology · Fredericksburg, VANPI 1457586208

Payments from drug & device makers

$515,951in general payments, 2019–2025

Across 776 payments — averaging $664.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$250K
  • Mirati Therapeutics, Inc.$158K
  • Partner Therapeutics, Inc.$76K
  • AstraZeneca$5K
  • Bristol Myers Squibb$4K
  • GSK$2K
  • plus $19K from 54 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Merck106$250,172
Mirati Therapeutics, Inc.20$158,468
Partner Therapeutics, Inc.8$76,275
AstraZeneca(2 entities)27$5,422
Bristol Myers Squibb20$4,157
GSK12$2,087
E.r. Squibb & Sons, L.L.C.42$1,889
Heron Therapeutics, Inc.5$1,651
Regeneron1$1,575
Novartis81$1,379
Pfizer89$1,334
Rigel Pharmaceuticals, Inc.3$1,234
Innate Pharma, Inc1$1,200
Incyte Corporation12$1,070
Janssen Scientific Affairs, LLC1$1,010
Johnson & Johnson(2 entities)50$818
Genentech USA, Inc.19$483
Astellas Pharma US Inc20$357
Amgen19$342
Regeneron Healthcare Solutions, Inc.9$286
Gilead(2 entities)14$272
Sanofi10$246
Puma Biotechnology, Inc.14$241
Jazz Pharmaceuticals Inc.11$241
EMD Serono, Inc.8$195
Servier Pharmaceuticals LLC10$188
Celltrion USA Inc.2$179
Daiichi Sankyo Inc.8$179
Seagen Inc.9$172
Eisai Inc.8$165
Bayer8$160
AbbVie8$159
Array Biopharma Inc7$151
Takeda Pharmaceuticals U.S.A., Inc.7$149
Pharmacyclics LLC, An Abbvie Company8$148
Dendreon Pharmaceuticals LLC6$122
Ipsen Biopharmaceuticals, Inc5$110
Beigene USA, Inc.5$107
Taiho Oncology, Inc.5$104
Lilly USA, LLC5$78
Boehringer Ingelheim3$74
Karyopharm Therapeutics Inc.3$71
ASD Specialty Healthcare, LLC2$67
GE HealthCare2$67
Tersera Therapeutics LLC3$66
ADC Therapeutics America, Inc.4$55
Organon5$50
Spectrum Pharmaceuticals Inc.2$50
Iovance Biotherapeutics, Inc.2$49
Secura Bio, Inc.4$49
Blue Earth Diagnostics2$48
CTI Biopharma Corp.2$46
AMAG Pharmaceuticals, Inc.3$44
Coherus Oncology, Inc.2$44
Exelixis Inc.1$39
Clovis Oncology, Inc.3$39
Adaptive Biotechnologies Corporation2$38
Tesaro, Inc.2$37
Verastem, Inc.2$36
Dova Pharmaceuticals2$35

How this compares

$515,951 in reported general payments places this provider in the 70th percentile of 95 medical oncology providers in Virginia.

See all medical oncology providers in Virginia →

Medicare billing

Part B allowed, 2024
$7,165,420
Medicare patients
1,412
Services billed
390,326

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other medical oncology in Fredericksburg

See the full list for Virginia →

Where these figures come from

Is this you, or does something look wrong? →